Detalhe da pesquisa
1.
A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Biol Blood Marrow Transplant
; 22(4): 698-704, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26785332